David M. Hashmall

David M. Hashmall

Partner Chairman, Goodwin
David M. Hashmall

David Hashmall serves as Chairman of Goodwin, a leading Global 50 firm with more than 900 lawyers across the United States, and in Europe and Asia. As Chairman, Mr. Hashmall is responsible for Goodwin’s overall strategy and growth, client relations and external communications. He chairs the firm’s Executive Committee and is a member of its Management and Allocations Committees.

Under his leadership, Goodwin has expanded in Europe with office openings in Frankfurt and Paris, and unveiled a new brand, reflecting its evolution from a strong regional to a top global firm. Mr. Hashmall also focuses on initiatives to enhance and expand diversity and inclusion at Goodwin and in the legal community.

He previously led the firm’s Litigation Department in New York for over 10 years. A partner in the IP Litigation Practice, Mr. Hashmall has more than 35 years of experience litigating complex commercial disputes at both the trial and appellate levels. His extensive IP litigation experience is concentrated on patent infringement in the pharmaceutical industry, with a specific focus on Hatch-Waxman litigation.

His efforts on behalf of clients have earned him distinction as a BTI Client Service All-Star, a designation determined by BTI’s annual in-house counsel survey. He has also been recognized as a leading IP lawyer by Chambers USA: America’s Leading Lawyers for Business, where clients have called him “a terrific trial lawyer” and “a great relationship partner.”

Professional Experience

Mr. Hashmall is a member of the Law Firm Pro Bono Project Advisory Committee of the Pro Bono Institute, whose mission is to explore and identify new approaches to and resources for the provision of legal services to the poor and disadvantaged.


Mr. Hashmall, who holds Martindale-Hubbell‘s highest rating of "AV®-Preeminent™," is recognized as a leader in his field by preeminent, peer-reviewed publications. His recognition includes:

  • Hatch-Waxman (Branded) Litigator of the Year, LMG Life Sciences
  • BTI Client Service All-Star
  • Chambers USA: America’s Leading Lawyers for Business
  • Intellectual Asset Management (IAM) Patent 1000, an annual listing of the world’s leading patent practitioners, where clients note that “he inspires the greatest degree of trust and he knows the judicial process inside out – he really is a terrific trial lawyer”
  • Managing IP Magazine, named an “IP Star”
  • Euromoney LMG Life Sciences Guide, named a “Life Sciences Star”
  • Legal 500 U.S.
  • New York Super Lawyers

Mr. Hashmall has been selected as a member of the Litigation Counsel of America, an invitation-only trial lawyer honorary society. While attending law school, he was on the staff of the Annual Survey of American Law.

Areas of Practice


Mr. Hashmall represents Teva Pharmaceuticals, the world’s largest generic pharmaceutical company, in Abbreviated New Drug Application (ANDA) litigations brought pursuant to the Hatch-Waxman Act and also in a wide variety of disputes involving licensing and joint-development agreements. His work for Teva has included leading Goodwin teams that:

  • Secured a summary judgment ruling invalidating Pfizer’s Celebrex® patent and allowing Teva to market a generic version of the non-steroidal anti-inflammatory drug (U.S. District Court for the Eastern District of Virginia)
  • Convinced the U.S. Court of Appeals for the Federal Circuit to invalidate all patent claims asserted by Pronova against Teva with respect to Teva’s ANDA to sell a generic version of Lovaza®, the first FDA-approved fish-oil derived prescription drug
  • Secured a summary judgment ruling of non-infringement allowing Teva to market a generic version of the anticoagulant Lovenox® (U.S. District Court for the District of Massachusetts)
  • Won a 16-day trial resulting in a judgment that the ANDAs filed by Sandoz/Momenta and Mylan infringe the patents covering Teva's branded product Copaxone®, the most prescribed treatment for relapse remitting multiple sclerosis (U.S. District Court for the Southern District of New York)
  • Achieved multiple litigation victories, in a two-year legal battle, allowing for the early launch of Teva’s generic version of Eloxatin®, a colon cancer drug (U.S. District Court for the Districts of New Jersey and Columbia; U.S. Court of Appeals for the Federal and District of Columbia Circuits)
  • Negotiated successful settlement after seven days of a jury trial involving Teva’s antitrust challenge of “product hopping” (i.e., making minor changes in drug formulations to prevent patents from expiring) by its competitors (U.S. District Court for the District of Delaware)



J.D., 1977
New York University School of Law
B.A., 1972
The Johns Hopkins University



New York


U.S. Supreme Court
U.S. Court of Appeals for the Second Circuit
U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers